Moleculin Biotech, Inc.
MBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $17,729 | $19,487 | $18,968 | $14,418 |
| G&A Expenses | $8,786 | $10,017 | $11,542 | $8,386 |
| SG&A Expenses | $8,786 | $10,017 | $11,542 | $8,386 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $126 | $127 | $130 | $164 |
| Operating Expenses | $26,641 | $29,631 | $30,640 | $22,968 |
| Operating Income | -$26,641 | -$29,631 | -$30,640 | -$22,968 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4,878 | -$138 | $1,615 | $7,074 |
| Pre-Tax Income | -$21,763 | -$29,769 | -$29,025 | -$15,894 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$21,763 | -$29,769 | -$29,025 | -$15,894 |
| % Margin | – | – | – | – |
| EPS | -158 | -376.75 | -380.5 | -221.75 |
| % Growth | 58.1% | 1% | -71.6% | – |
| EPS Diluted | -158 | -376.75 | -380.5 | -221.75 |
| Weighted Avg Shares Out | 138 | 79 | 76 | 72 |
| Weighted Avg Shares Out Dil | 138 | 79 | 76 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $550 | $1,368 | $240 | $306 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $126 | $127 | $130 | $164 |
| EBITDA | -$26,515 | -$29,504 | -$30,510 | -$22,804 |
| % Margin | – | – | – | – |